Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Director | September 04, 2020 | September 17, 2020 |
| GLOBUS MEDICAL INCGMED · Entity 3496 | Director | January 21, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDOLOGIX INC /DE/
Report date September 04, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-09-04 · Sale · Disposed 2,582 · Balance 49,262 Row 2 · 2020-09-04 · Sale · Disposed 33,709 · Balance 15,553 Row 3 · 2020-09-04 · Sale · Disposed 15,553 · Balance 0 |
GLOBUS MEDICAL INC
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $94.15 · Expires 2036-01-21 | Direct | 15,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 15,000 · Balance 15,000 F1: These options were granted on January 21, 2026, and will vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 1, 2019 16:29 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 2,000 | Not disclosed Strike: $82.60 | Not disclosed |
DisclosureSEC source: 0001013606-19-000167 · wf-form4_156996175134943.xml · derivative · entry 3 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2021-05-25 F4 · shares: 100% of the options vested on May 25, 2012. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 5,000 shares of common stock granted to the reporting person on December 10, 2009, (ii) an option for 2,000 shares of common stock granted to the reporting person on May 20, 2010, and (iii) an option for 2,000 shares of common stock granted to the reporting person on May 25, 2011. In exchange, the reporting person received a new stock option, for 2,834 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:29 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 2,000 | Not disclosed Strike: $43.60 | Not disclosed |
DisclosureSEC source: 0001013606-19-000167 · wf-form4_156996175134943.xml · derivative · entry 2 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2020-05-20 F3 · shares: 100% of the options vested on May 20, 2011. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 5,000 shares of common stock granted to the reporting person on December 10, 2009, (ii) an option for 2,000 shares of common stock granted to the reporting person on May 20, 2010, and (iii) an option for 2,000 shares of common stock granted to the reporting person on May 25, 2011. In exchange, the reporting person received a new stock option, for 2,834 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:29 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 5,000 | Not disclosed Strike: $43.80 | Not disclosed |
DisclosureSEC source: 0001013606-19-000167 · wf-form4_156996175134943.xml · derivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-12-10 F1 · shares: Options vested equally over four years. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 5,000 shares of common stock granted to the reporting person on December 10, 2009, (ii) an option for 2,000 shares of common stock granted to the reporting person on May 20, 2010, and (iii) an option for 2,000 shares of common stock granted to the reporting person on May 25, 2011. In exchange, the reporting person received a new stock option, for 2,834 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:19 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 21,913 | $6.67 Strike: $6.67 | $146,159.71 |
DisclosureSEC source: 0001013606-19-000140 · wf-form4_156512637224507.xml · derivative · entry 2 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,913 Underlying: Common Stock · 21,913 shares Expires 2029-08-05 F2 · shares: 100% of the option award shall vest on August 5, 2020. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:19 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 13,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000140 · wf-form4_156512637224507.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,601 F1 · shares: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock. Read SEC document |
| August 05, 2019 Filed Sep 12, 2019 20:12 UTC Amendment | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 9,023 | $6.67 Strike: $6.67 | $60,183.41 |
DisclosureSEC source: 0001013606-19-000158 · wf-form4a_156833351370771.xml · derivative · entry 2 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,023 Underlying: Common Stock · 9,023 shares Expires 2029-08-05 F3 · shares: 100% of the option award shall vest on August 5, 2020. F4 · shares: On August 6, 2019, the reporting person filed a Form 4 which inadvertently reported that he acquired an option to purchase 21,913 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person acquired an option to purchase 9,023 shares of the issuer's common stock, as originally approved by the issuer's board of directors. Read SEC document |
| August 05, 2019 Filed Sep 12, 2019 20:12 UTC Amendment | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 20,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000158 · wf-form4a_156833351370771.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,097 F1 · shares: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock. F2 · shares: On August 6, 2019, the reporting person filed a Form 4 which inadvertently reported that he was awarded 13,494 time-based restricted stock units by the issuer. In fact, as reported in this amendment, the reporting person was awarded 20,990 time-based restricted stock units by the issuer, as originally approved by the issuer's board of directors. Read SEC document |
| January 22, 2019 Filed Feb 11, 2019 16:43 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-19-008975 · doc4.xml · derivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 20:02 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 181,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000015 · wf-form4_154647730796418.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,065 F1 · kind: 100% of the time-based restricted stock unit award shall vest on December 30, 2019 and shall settle in shares of common stock. Read SEC document |
| May 09, 2018 Filed May 11, 2018 16:07 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 46,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-18-000073 · wf-form4_152606916771725.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,735 F1 · kind: 100% of the time-based restricted stock unit award shall vest on May 9, 2019 and shall settle in shares of common stock. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 16:20 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $43.77 | $0.00 |
DisclosureSEC source: 0001209191-18-005104 · doc4.xml · derivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2028-01-22 F1 · derivative.exercise_date: These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2018, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:34 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 34,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000096 · wf-form4_149643565034901.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,921 Read SEC document |
| May 22, 2017 Filed May 23, 2017 11:06 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Stock | 22,522 | $4.43 | $99,772.46 |
DisclosureSEC source: 0001013606-17-000057 · wf-form4_149555196652725.xml · nonDerivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,689 Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 17:58 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $26.27 | $0.00 |
DisclosureSEC source: 0001209191-17-006843 · doc4.xml · derivative · entry 1 Lemaitre Dan · CIK 0001478479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2027-01-30 F1 · derivative.exercise_date: These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2017, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.